Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Postop Taxane/Platinum Competes With Standard Therapy

Publish date:: April 4, 2019

Key clinical point: For patients with endometrial cancer at high risk of progression, receiving a combination of taxane and platinum chemotherapy after surgery offers similar efficacy and tolerability as doxorubicin and cisplatin, the standard therapy.

Major finding: The 5-year overall survival rate was 82.7% for doxorubicin/cisplatin, 86.1% for paclitaxel/carboplatin, and 88.1% for docetaxel/cisplatin (P = .67).

Study details: A prospective, phase 3 trial involving 788 patients with endometrial cancer at high risk of progression.

Disclosures: The study was funded by a Health Labour Sciences Research Grant with nonspecific funding from AstraZeneca, Eisai, Bristol-Myers Squibb, and others. The investigators reported financial relationships with Chugai, Sanofi, Takeda, AbbVie, and others.

Citation:

Nomura H et al. JAMA Oncol. 2019 Mar 21. doi: 10.1001/jamaoncol.2019.0001.

This Week's Must Reads

Claims data improves cancer registry information on treatment,

Benefits and drawbacks found for risk-based lung cancer screening tools,

Patient-reported outcomes support first-line pembrolizumab for NSCLC,

Bilateral mastectomy reduces second breast cancer risk, but not deaths,

Study Links DLBCL, MZL in Sjogren’s Syndrome,

Must Reads in Gynecologic Cancer

Sequential CRT, immunotherapy nets high PFS in node-positive cervical cancer,

In recurrent ovarian cancer, secondary surgery does not extend survival,

Surgical staging improves cervical cancer outcomes,

Sentinel node biopsy safe for women with vulval cancer,

HER2-Positive Solid Tumors: Molecule Exhibits Antitumor Activity,